SG11201407447XA - N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide - Google Patents
N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamideInfo
- Publication number
- SG11201407447XA SG11201407447XA SG11201407447XA SG11201407447XA SG11201407447XA SG 11201407447X A SG11201407447X A SG 11201407447XA SG 11201407447X A SG11201407447X A SG 11201407447XA SG 11201407447X A SG11201407447X A SG 11201407447XA SG 11201407447X A SG11201407447X A SG 11201407447XA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- pentahydroxyhexyl
- dihydroquinoline
- carboxamide
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644054P | 2012-05-08 | 2012-05-08 | |
| PCT/US2013/039911 WO2013169746A2 (fr) | 2012-05-08 | 2013-05-07 | N-ethyl-4-hydroxyl-1-méthyl-5-(méthyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phényl-1,2-dihydroquinoléine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407447XA true SG11201407447XA (en) | 2015-02-27 |
Family
ID=49551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407447XA SG11201407447XA (en) | 2012-05-08 | 2013-05-07 | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8809537B2 (fr) |
| EP (1) | EP2697201A4 (fr) |
| KR (1) | KR20150022816A (fr) |
| CN (1) | CN104395291B (fr) |
| AR (1) | AR090975A1 (fr) |
| AU (1) | AU2013259779B2 (fr) |
| BR (1) | BR112014028121A2 (fr) |
| CA (1) | CA2873258A1 (fr) |
| EA (1) | EA201492029A1 (fr) |
| HK (1) | HK1207080A1 (fr) |
| IL (1) | IL235338A0 (fr) |
| IN (1) | IN2014MN02485A (fr) |
| MX (1) | MX2014013664A (fr) |
| NZ (1) | NZ630549A (fr) |
| SG (1) | SG11201407447XA (fr) |
| TW (1) | TW201350467A (fr) |
| UY (1) | UY34791A (fr) |
| WO (1) | WO2013169746A2 (fr) |
| ZA (1) | ZA201408825B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| CA2863409A1 (fr) | 2012-02-16 | 2013-08-22 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoleine carboxamide, sa preparation et son utilisation |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2890194A1 (fr) * | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Sels d'amine de laquinimod |
| SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| BR112016024943A2 (pt) | 2014-04-29 | 2018-06-26 | Teva Pharma | laquinimod para o tratamento de casos de esclerose múltipla remitente recorrente (emrr) com status de alta deficiência |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2159804A (en) * | 1937-11-23 | 1939-05-23 | Du Pont | N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US6043006A (en) * | 1997-09-04 | 2000-03-28 | Fuji Photo Film Co., Ltd. | 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| ATE300285T1 (de) | 1999-06-07 | 2005-08-15 | Altana Pharma Ag | Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor |
| US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| AU2006304672B2 (en) | 2005-10-19 | 2013-01-10 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR101495327B1 (ko) | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| CA2686545C (fr) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Composes substitues de morpholinyle |
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| EP2337779B1 (fr) | 2008-09-03 | 2017-04-19 | Teva Pharmaceutical Industries Ltd. | Modulateurs 2-oxo-1,2-dihydro-quinoléines de la fonction immunitaire |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| EP2228367A1 (fr) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH |
| SG10201403397TA (en) | 2009-06-19 | 2014-10-30 | Teva Pharma | Treatment Of Multiple Sclerosis With Laquinimod |
| RS54707B1 (en) | 2009-07-30 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | TREATMENT OF CROWN LAKVINIMOD DISEASE |
| RS55071B1 (sr) | 2009-08-10 | 2016-12-30 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| CA2791709A1 (fr) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Traitement de la polyarthrite rhumatoide au moyen d'une combinaison de laquinimod et de methotrexate |
| WO2011109536A1 (fr) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Traitement de l'arthrite de lupus à l'aide du laquinimod |
| PE20181523A1 (es) | 2010-03-03 | 2018-09-24 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod |
| MX2013000332A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma. |
| SG186948A1 (en) | 2010-07-09 | 2013-02-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| JP2012047974A (ja) * | 2010-08-26 | 2012-03-08 | Toshiba Corp | 映像表示装置及び映像表示方法 |
| RU2013120556A (ru) * | 2010-10-14 | 2014-11-20 | Иммунар Аб | 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr |
| AU2011338647A1 (en) | 2010-12-07 | 2013-07-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| KR20140054166A (ko) | 2011-07-28 | 2014-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 글라티라머 아세테이트의 병용에 의한 다발성 경화증의 치료 |
| AU2012286701A1 (en) | 2011-07-28 | 2014-03-06 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2013
- 2013-05-02 TW TW102115767A patent/TW201350467A/zh unknown
- 2013-05-07 IN IN2485MUN2014 patent/IN2014MN02485A/en unknown
- 2013-05-07 AU AU2013259779A patent/AU2013259779B2/en not_active Expired - Fee Related
- 2013-05-07 CN CN201380029448.XA patent/CN104395291B/zh not_active Expired - Fee Related
- 2013-05-07 UY UY0001034791A patent/UY34791A/es not_active Application Discontinuation
- 2013-05-07 NZ NZ630549A patent/NZ630549A/en not_active IP Right Cessation
- 2013-05-07 CA CA2873258A patent/CA2873258A1/fr not_active Abandoned
- 2013-05-07 SG SG11201407447XA patent/SG11201407447XA/en unknown
- 2013-05-07 BR BR112014028121A patent/BR112014028121A2/pt not_active IP Right Cessation
- 2013-05-07 EA EA201492029A patent/EA201492029A1/ru unknown
- 2013-05-07 WO PCT/US2013/039911 patent/WO2013169746A2/fr active Application Filing
- 2013-05-07 KR KR20147034461A patent/KR20150022816A/ko not_active Application Discontinuation
- 2013-05-07 MX MX2014013664A patent/MX2014013664A/es unknown
- 2013-05-07 EP EP13750833.9A patent/EP2697201A4/fr not_active Withdrawn
- 2013-05-07 US US13/888,709 patent/US8809537B2/en not_active Expired - Fee Related
- 2013-05-07 AR ARP130101569A patent/AR090975A1/es unknown
-
2014
- 2014-10-26 IL IL235338A patent/IL235338A0/en unknown
- 2014-12-02 ZA ZA2014/08825A patent/ZA201408825B/en unknown
-
2015
- 2015-08-12 HK HK15107804.4A patent/HK1207080A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1207080A1 (en) | 2016-01-22 |
| NZ630549A (en) | 2016-01-29 |
| EP2697201A2 (fr) | 2014-02-19 |
| WO2013169746A3 (fr) | 2013-12-05 |
| IN2014MN02485A (fr) | 2015-07-17 |
| TW201350467A (zh) | 2013-12-16 |
| EP2697201A4 (fr) | 2014-11-26 |
| IL235338A0 (en) | 2014-12-31 |
| CN104395291A (zh) | 2015-03-04 |
| AR090975A1 (es) | 2014-12-17 |
| CA2873258A1 (fr) | 2013-11-14 |
| AU2013259779A1 (en) | 2014-12-18 |
| MX2014013664A (es) | 2015-04-17 |
| AU2013259779B2 (en) | 2017-06-08 |
| US20130345256A1 (en) | 2013-12-26 |
| CN104395291B (zh) | 2017-07-28 |
| ZA201408825B (en) | 2016-07-27 |
| EA201492029A1 (ru) | 2015-06-30 |
| BR112014028121A2 (pt) | 2017-06-27 |
| UY34791A (es) | 2013-11-29 |
| KR20150022816A (ko) | 2015-03-04 |
| US8809537B2 (en) | 2014-08-19 |
| WO2013169746A2 (fr) | 2013-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2762476A4 (fr) | Dérivé de 1,2,4-triazine-6-carboxamide | |
| HK1207080A1 (en) | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide n--4--1--5-((23456-))-2--n- -12 --3- | |
| HK1192757A1 (zh) | 取代的 -芳基- -苯基- -三嗪- -胺 | |
| HK1207317A1 (en) | Substituted 1,6-naphthyridines 16- | |
| HK1203974A1 (en) | Anti -transglutaminase 2 antibodies - 2 | |
| GB201214120D0 (en) | Yota 070812 | |
| PL2851075T3 (pl) | Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu | |
| GB201200518D0 (en) | Wizz-through 2 (cielings) | |
| GB201210424D0 (en) | Poop - pole N?2 | |
| GB201200323D0 (en) | Easihang 45?/90? | |
| GB201220196D0 (en) | Magno-rebel 1 | |
| GB201214054D0 (en) | Pakaging 0 | |
| GB201208532D0 (en) | SockScreen 2 | |
| GB201206581D0 (en) | CityJaw 1830 | |
| GB201200834D0 (en) | Vinsole 3 | |
| GB201214001D0 (en) | Concept 32 | |
| GB201214039D0 (en) | Concept 29 | |
| GB201214046D0 (en) | Concept 4 | |
| GB201214044D0 (en) | Concept 31 | |
| GB201214072D0 (en) | Concept 50 | |
| GB201214037D0 (en) | Concept 25 | |
| GB201214035D0 (en) | Concept 23 | |
| GB201214034D0 (en) | Concept 22 | |
| GB201214041D0 (en) | Concept 30 | |
| GB201214006D0 (en) | Concept 33 |